Paracoccidioidomycosis is a systemic fungal disease occurring in Latin America that is associated with rural environments and agricultural activities. However, the incidence and prevalence of paracoccidiodomycosis is underestimated because of the lack of compulsory notification. If paracoccidiodomycosis is not diagnosed and treated early and adequately, the endemic fungal infection could result in serious sequelae. While the Paracoccidioides brasiliensis ( P. brasiliensis ) complex has been known to be the causal agent of paracoccidiodomycosis, a new species, Paracoccidioides lutzii ( P. lutzii ), has been reported in Rondônia, where the disease has reached epidemic levels, and in the Central West and Pará. Accurate diagnoses and availability of antigens that are reactive with the patients’ sera remain significant challenges. Therefore, the present guidelines aims to update the first Brazilian consensus on paracoccidioidomycosis by providing evidence-based recommendations for bedside patient management. This consensus summarizes etiological, ecoepidemiological, molecular epidemiological, and immunopathological data, with emphasis on clinical, microbiological, and serological diagnosis and management of clinical forms and sequelae, as well as in patients with comorbidities and immunosuppression. The consensus also includes discussion of outpatient treatments, severe disease forms, disease prevalence among special populations and resource-poor settings, a brief review of prevention and control measures, current challenges and recommendations.

Background: This review article summarizes and updates the knowledge on paracoccidioidomycosis.P lutziiand the cryptic species ofP. brasiliensisand their geographical distribution in Latin America, explaining the difficulties observed in the serological diagnosis.Objectives: Emphasis has been placed on some genetic factors as predisposing condition for paracoccidioidomycosis. Veterinary aspects were focused, showing the wide distribution of infection among animals. The cell-mediated immunity was better characterized, incorporating the recent findings.Methods: Serological methods for diagnosis were also compared for their parameters of accuracy, including the analysis of relapse.Results: Clinical forms have been better classified in order to include the pictures less frequently observesiod.Conclusion: Itraconazole and the trimethoprim-sulfamethoxazole combination was compared regarding efficacy, effectiveness and safety, demonstrating that azole should be the first choice in the treatment of paracoccidioidomycosis.

Paracoccidioides lutzii is a new agent of paracoccidioidomycosis (PCM) and has its epicenter localized to the Central-West region of Brazil. Serological diagnosis of PCM caused by P. lutzii has not been established. This study aimed to develop new antigenic preparations from P. lutzii and to apply them in serological techniques to improve the diagnosis of PCM due to P. lutzii. Paracoccidioides lutzii exoantigens, cell free antigen (CFA), and a TCA-precipitated antigen were evaluated in immunodiffusion (ID) tests using a total of 89 patient sera from the Central-West region of Brazil. Seventy-two sera were defined as reactive for P. brasiliensis using traditional antigens (AgPbB339 and gp43). Non-reactive sera for traditional antigens (n = 17) were tested with different P. lutzii preparations and P. lutzii CFA showed 100% reactivity. ELISA was found to be a very useful test to titer anti-P. lutzii antibodies using P. lutzii-CFA preparations. Sera from patients with PCM due to P. lutzii presented with higher antibody titers than PCM due to P. brasiliensis and heterologous sera. In western blot, sera from patients with PCM due to P. lutzii were able to recognize antigenic molecules from the P. lutzii-CFA antigen, but sera from patients with PCM due to P. brasiliensis could not recognize any P. lutzii molecules. Due to the facility of preparing P. lutzii CFA antigens we recommend its use in immunodiffusion tests for the diagnosis of PCM due to P. lutzii. ELISA and western blot can be used as complementary tests. Tropical diseases, such as paracoccidioidomycosis, are the most common type of neglected diseases. From 1980 to 1995, 3,181 deaths from paracoccidioidomycosis occurred in Brazil, representing the eighth most common cause of death from predominantly chronic or recurrent types of infectious and parasitic diseases, showing considerable magnitude and low visibility. Paracoccidioidomycosis is traditionally assumed to be caused solely by Paracoccidioides brasiliensis, but a new species, Paracoccidioides lutzii, was discovered in the Central-Western region of Brazil. Thus, new antigenic preparations and tests for an accurate differential diagnosis between these two species appear to be needed. This study aimed to develop new antigenic preparations from P. lutzii isolates to improve the diagnosis of paracoccidioidomycosis. We used patient serum samples predominantly from the Central-Western region of Brazil. Various antigenic preparations were tested, and a cell free antigen derived from P. lutzii was an excellent antigen for serological diagnosis and able to diagnose 100% of sera from patients with PCM due to P. lutzii.

Over the last three decades, the epidemiological profile of visceral leishmaniasis (VL) has changed with epidemics occurring in large urban centers of Brazil, an increase in HIV/AIDS co-infection, and a significant increase in mortality. The objective of this study was to identify the risk factors associated with death among adult patients with VL from an urban endemic area of Brazil. A prospective cohort study included 134 adult patients with VL admitted to the University Hospital of the Federal University of Mato Grosso do Sul between August 2011 and August 2013. Patients ranged from 18 to 93 years old, with a mean age of 43.6 (±15.7%). Of these patients, 36.6% were co-infected with HIV/AIDS, and the mortality rate was 21.6%. In a multivariate analysis, the risk factors associated with death were secondary bacterial infection (42.86, 5.05–363.85), relapse (12.17, 2.06–71.99), edema (7.74, 1.33–45.05) and HIV/AIDS co-infection (7.33, 1.22–43.98). VL has a high mortality rate in adults from endemic urban areas, especially when coinciding with high rates of HIV/AIDS co-infection. Visceral Leishmaniasis (VL) is considered a neglected disease by the World Health Organization (WHO). Over the last two decades, the epidemiological profile of VL has changed with epidemics occurring in large urban centers of Brazil with increased HIV/AIDS co-infection and mortality. Understanding the factors that lead to death in these patients is important to improve public health strategies and reduce mortality. We performed a prospective cohort study between August 2011 and August 2013 of 134 adult patients with VL from Campo Grande urban area. Approximately 40% had AIDS and 22% died during the 12-month follow-up. Relapses, bacterial infection, AIDS and edema were strongly associated with death among VL patients in the Brazilian urban centers. All VL patients should be screened for HIV and bacterial infection as well as to prevent VL relapses.